Cargando…

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Ashok Kumar, Prashanth, Basnet, Alina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579829/ https://www.ncbi.nlm.nih.gov/pubmed/37854158 http://dx.doi.org/10.21037/tlcr-23-566

Ejemplares similares

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
por: Brueckl, Wolfgang M., et al.
Publicado: (2020)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer
por: Tang, Yichun, et al.
Publicado: (2022)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
por: Aldea, Mihaela, et al.
Publicado: (2020)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment—therapeutic indication or therapeutic efficacy?
por: Kawase, Akikazu
Publicado: (2022)

CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy
por: Jain, Swati, et al.
Publicado: (2023)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer
por: Tanaka, Satomi, et al.
Publicado: (2022)

Challenges of predicting immune checkpoint therapy responders in lung cancer
por: Marwitz, Sebastian
Publicado: (2019)

Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Lin, Zhihuan, et al.
Publicado: (2020)

Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
por: Matsukane, Ryosuke, et al.
Publicado: (2021)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer
por: Jiang, Jiehan, et al.
Publicado: (2021)

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
por: Karachaliou, Niki, et al.
Publicado: (2018)

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer
por: Lee, Ye Jin, et al.
Publicado: (2022)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
por: Corke, Lucy K., et al.
Publicado: (2022)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Expanding our understanding of clinical laboratory testing in male infertility patients
por: Esteves, Sandro C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jiafl2trh1b9nfrkrsobcff259